Molecular abnormalities in lymphomas;Les anomalies moléculaires dans les lymphomes

Bulletin du Cancer

Volumn 97, Issue 11, 2010, Pages 1347-1364

  Delsol, G ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Gene expression profiling; Lymphoma; Molecular abnormalities; Transcriptome; WHO classification

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CHEMOKINE RECEPTOR CXCR5; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CXCL13 CHEMOKINE; CYCLIN D1; ENZYME INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DIAGNOSTIC VALUE; DNA MICROARRAY; ENZYME ACTIVATION; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; GENETIC DISORDER; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NK T CELL LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

EID: 78650146736     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1214     Document Type: Review

References (78)

1. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001 ; 81 : 1331-8. (Pubitemid 32980155)
2. Swerdlow S, Campo E, Harris NL, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008, Lyon.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 ; 403 : 503-11. (Pubitemid 30082188)
4. Cooper GM, Hausman R. The Cell. A molecular Approach. Washington : ASM Press, 2004.
5. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008 ; 105 : 13520-5.
6. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004 ; 350 : 1828-37. (Pubitemid 38917249)
7. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002 ; 346 : 1937-47. (Pubitemid 34651353)
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 ; 103 : 275-82. (Pubitemid 38029949)
9. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986 ; 164 : 315-20. (Pubitemid 16069242)
10. Albinger-Hegyi A, Hochreutener B, Abdou MT, et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol 2002 ; 160 : 823-32. (Pubitemid 34224572)
11. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000 ; 27 : 85-94.
12. Galoin S, al Saati T, Schlaifer D, Huynh A, Attal M, Delsol G. Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. Br J Haematol 1996 ; 94 : 676-84. (Pubitemid 26308901)
13. Agopian J, Navarro JM, Gac AC, et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 2009 ; 206 : 1473-83.
14. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 2009 ; 113 : 6386-91.
15. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998 ; 91 : 4677-85. (Pubitemid 28270317)
16. Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008 ; 111 : 5433-9.
17. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004 ; 351 : 2159-69. (Pubitemid 39507628)
18. Harjunpaa A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumor microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006 ; 135 : 33-42. (Pubitemid 44339457)
19. Isaacson P, Wright D. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983 ; 52 : 1410-6. (Pubitemid 13017202)
20. Anonymous. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997 ; 89 : 3909-18.
21. Doglioni C, Wotherspoon AC, Moschini A, de Boni M, Isaacson P. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992 ; 339 : 834-5.
22. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa- associated lymphoid tissue lymphomas. Blood 1999 ; 93 : 3601-9. (Pubitemid 29249804)
23. Ott G, Katzenberger T, Greiner A, et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997 ; 57 : 3944-8. (Pubitemid 27427681)
24. Willis TG, Jadayel DM, Du MQ, et al. BCL10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999 ; 96 : 35-45. (Pubitemid 29044151)
25. Thome M. Multifunctional roles for MALT1 in T-cell activation. Nature Rev Immunol 2008 ; 8 : 495-500. (Pubitemid 351913678)
26. Farinha P, Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005 ; 23 : 6370-8. (Pubitemid 46218849)
27. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004 ; 350 : 239-48. (Pubitemid 38067636)
28. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997 ; 24 : 457-61. (Pubitemid 27432373)
29. Vargas RL, Fallone E, Felgar RE, et al. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk Res 2006 ; 30 : 547-51. (Pubitemid 43374583)
30. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993 ; 342 : 575-7. (Pubitemid 23259233)
31. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001 ; 357 : 39-40. (Pubitemid 32056501)
32. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999 ; 93 : 4365-74. (Pubitemid 29279280)
33. Camacho E, Hernandez L, Hernandez S, et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidyl-inositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002 ; 99 : 238-44.
34. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000 ; 97 : 2773-8. (Pubitemid 30159247)
35. Campo E, Raffeld M, Jaffe E. Mantle-cell lymphoma. Semin Hematol 1999 ; 36 : 115-27.
36. Swerdlow SH, Williams M. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of three decades. Human Pathol 2002 ; 33 : 7-20. (Pubitemid 34112948)
37. Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 2006 ; 91 : 11-6. (Pubitemid 43235380)
38. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003 ; 3 : 185-97. (Pubitemid 37443390)
39. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007 ; 25 : 1216-22. (Pubitemid 46640567)
40. Harris NL, Horning S. Burkitt's lymphoma: the message from microarrays. N Engl J Med 2006 ; 354 : 2495-8.
41. Bellan C, De Falco G, Lazzi S, Leoncini L. Pathologic aspects of AIDS malignancies. Oncogene 2003 ; 22 : 6639-45.
42. Croce CM, Nowell P. Molecular basis of human B cell neoplasia. Blood 1985 ; 65 : 1-7. (Pubitemid 15191031)
43. Boxer LM, Dang CV. Translocations involving c-Myc and c-Myc function. Oncogene 2001 ; 20 : 5595-610.
44. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006 ; 354 : 2419-30. (Pubitemid 43855045)
45. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006 ; 354 : 2431-42.
46. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007 ; 117 : 823-34. (Pubitemid 46348541)
47. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri S. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007 ; 92 : 566-7. (Pubitemid 350144307)
48. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006 ; 24 : 2472-9. (Pubitemid 46630624)
49. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angio-immunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007 ; 109 : 4952-63. (Pubitemid 46827794)
50. Delsol G, Jaffe ES, Falini B, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In : Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon : International Agency for Research on Cancer, 2008.
51. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 ; 96 : 3681-95.
52. Delsol G, Gatter KC, Stein H, et al. Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet 1984 ; 2 : 1124-9.
53. Mason DY, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Br J Haematol 1990 ; 74 : 161-8. (Pubitemid 20041090)
54. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994 ; 263 : 1281-4. (Pubitemid 24107549)
55. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999 ; 93 : 3088-95. (Pubitemid 29200802)
56. Mason DY, Pulford KA, Bischof D, et al. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998 ; 58 : 1057-62. (Pubitemid 28182479)
57. Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003 ; 37 : 427-32. (Pubitemid 36775787)
58. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: two cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000 ; 95 : 3204-7. (Pubitemid 30321174)
59. Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004 ; 61: 2939-53. (Pubitemid 40104592)
60. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008 ; 8 : 11-23.
61. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004 ; 103 : 1464-71. (Pubitemid 38168663)
62. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007 ; 109 : 2156-64. (Pubitemid 46348218)
63. Quintanilla-Martinez L, Pittaluga S, Miething C, et al. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood 2006 ; 108 : 2029-36. (Pubitemid 44395017)
64. Piva R, Pellegrino E, Inghirami G. Identification and validation of the anaplastic large cell lymphoma signature. Adv Exp Med Biol 2007 ; 604 : 129-36.
65. Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006 ; 116 : 3171-82. (Pubitemid 44878631)
66. Delsol G, Lamant L, Mariamé B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997 ; 89 : 1483-90. (Pubitemid 27097438)
67. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of six cases. Blood 2003 ; 102 : 2568-73. (Pubitemid 37193597)
68. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001 ; 25 : 1364-71. (Pubitemid 33022051)
69. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001 ; 159 : 411-5. (Pubitemid 32751070)
70. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine-kinase gene in neuroblastoma. Am J Pathol 2000 ; 156 : 1711-21. (Pubitemid 30646709)
71. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 ; 448 : 561-6. (Pubitemid 47206930)
72. Jager R, Hahne J, Jacob A, et al. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 2005 ; 25 : 3191-6. (Pubitemid 41105188)
73. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003 ; 22 : 7750-61. (Pubitemid 37485534)
74. Giuriato S, Faumont N, Bousquet E, et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther 2007 ; 6 : 1318-23. (Pubitemid 351590389)
75. Giuriato S, Foisseau M, Dejean E, et al. Conditional TPM3-ALK and NPM-ALK transgenic micedevelop reversible ALK-positive early B cell lymphoma/leukemia. Blood 2010 (sous presse).
76. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009 ; 9 : 331-56.
77. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007 ; 110 : 972-8. (Pubitemid 47267436)
78. Brousset P. Is the Epstein-Barr virus infection relevant in lymphomagenesis? Human pathology 2002 ; 33 : 143-5.